WST West Pharmaceutical Services

Q3 2025 10-Q

Filed: Oct 23, 2025Period ending Sep 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

West Pharmaceutical Services (WST) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 23, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $805M, up 7.7% YoY ($57.7M increase) for Q3 2025; Proprietary Products $647.5M (+7.7%), Contract-Manufactured Products $157.1M (+8.0%)
• Operating margin 20.8% vs 21.6% YoY Q3 2025 (down 0.8 pts); adjusted operating margin 21.1% vs 21.5%; gross margin 36.6% vs 35.4% (up 1.2 pts)

+3 more insights

Risk Factors

• Continued COVID-19 impact on supply chain and customer demand remains key operational risk
• Exposure to foreign currency fluctuations affecting reported results due to international sales

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$805M

▲ +7.7% YoY▲ +5.0% QoQ

Net Income

$140M

▲ +2.9% YoY▲ +6.2% QoQ

Net Margin

17.4%

▼ -81bp YoY▲ +20bp QoQ

Source: XBRL data from West Pharmaceutical Services Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on West Pharmaceutical Services

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.